tech
April 15, 2026
The Musician-Turned-Biotech-Founder Waiting to Fundraise
Aloe Blacc sits down with TechCrunch’s Equity Podcast to talk about his transition from music to biotech, why he’s building a cancer drug company, and why he’s choosing not to fundraise yet.
TL;DR
- Aloe Blacc is developing a cancer drug platform, focusing on pancreatic cancer, after a personal experience with COVID-19.
- He encountered regulatory and scientific trial challenges when trying to fund biotech research through philanthropy.
- Blacc is leveraging a University of Houston molecule discovery platform to expedite drug development.
- He believes record labels will control the economics of AI-generated music, not artists or AI companies.
- His next album will feature live musicians, despite his exploration of AI in music.
Continue reading the original article